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A B S T R A C T
Background
The placenta has an essential role in determining the outcome of pregnancy. Consequently, biochemical measurement of placentally-
derived factors has been suggested as a means to improve fetal and maternal outcome of pregnancy.
Objectives
To assess whether clinicians’ knowledge of the results of biochemical tests of placental function is associated with improvement in fetal
or maternal outcome of pregnancy.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 July 2015) and reference lists of retrieved studies.
Selection criteria
Randomised, cluster-randomised or quasi-randomised controlled trials assessing the merits of the use of biochemical tests of placental
function to improve pregnancy outcome.
Studies were eligible if they compared women who had placental function tests and the results were available to their clinicians with
women who either did not have the tests, or the tests were done but the results were not available to the clinicians. The placental function
tests were any biochemical test of placental function carried out using the woman’s maternal biofluid, either alone or in combination
with other placental function test/s.
Data collection and analysis
Two review authors independently assessed trials for inclusion, extracted data and assessed trial quality. Authors of published trials were
contacted for further information.
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Main results
Three trials were included, two quasi-randomised controlled trials and one randomised controlled trial. One trial was deemed to be at
low risk of bias while the other two were at high risk of bias. Different biochemical analytes were measured - oestrogen was measured
in one trial and the other two measured human placental lactogen (hPL). One trial did not contribute outcome data, therefore, the
results of this review are based on two trials with 740 participants.
There was no evidence of a difference in the incidence of death of a baby (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.36 to
2.13, two trials, 740 participants (very low quality evidence)) or the frequency of a small-for-gestational-age infant (RR 0.44, 95%
CI 0.16 to 1.19, one trial, 118 participants (low quality evidence)).
In terms of this review’s secondary outcomes, there was no evidence of a clear difference between women who had biochemical tests of
placental function compared with standard antenatal care for the incidence of stillbirth (RR 0.56, 95% CI 0.16 to 1.88, two trials, 740
participants (very low quality evidence)) or neonatal death (RR 1.62, 95% CI 0.39 to 6.74, two trials, 740 participants, very low quality
evidence)) although the directions of any potential effect were in opposing directions. There was no evidence of a difference between
groups in elective delivery (RR 0.98, 95% CI 0.84 to 1.14, two trials, 740 participants (low quality evidence)), caesarean section (one
trial, RR 0.48, 95% CI 0.15 to 1.52, one trial, 118 participants (low quality evidence)), change in anxiety score (mean difference -2.40,
95% CI -4.78 to -0.02, one trial, 118 participants), admissions to neonatal intensive care (RR 0.32, 95% CI 0.03 to 3.01, one trial,
118 participants), and preterm birth before 37 weeks’ gestation (RR 2.90, 95% CI 0.12 to 69.81, one trial, 118 participants). One
trial (118 participants) reported that there were no cases of serious neonatal morbidity. Maternal death was not reported.
A number of this review’s secondary outcomes relating to the baby were not reported in the included studies, namely: umbilical artery
pH < 7.0, neonatal intensive care for more than seven days, very preterm birth (< 32 weeks’ gestation), need for ventilation, organ
failure, fetal abnormality, neurodevelopment in childhood (cerebral palsy, neurodevelopmental delay). Similarly, a number of this
review’s maternal secondary outcomes were not reported in the included studies (admission to intensive care, high dependency unit
admission, hospital admission for > seven days, pre-eclampsia, eclampsia, and women’s perception of care).
Authors’ conclusions
There is insufficient evidence to support the use of biochemical tests of placental function to reduce perinatal mortality or increase
identification of small-for-gestational-age infants. However, we were only able to include data from two studies that measured oestrogens
and hPL. The quality of the evidence was low or very low.
Two of the trials were performed in the 1970s on women with a variety of antenatal complications and this evidence cannot be
generalised to women at low-risk of complications or groups of women with specific pregnancy complications (e.g. fetal growth
restriction). Furthermore, outcomes described in the 1970s may not reflect what would be expected at present. For example, neonatal
mortality rates have fallen substantially, such that an infant delivered at 28 weeks would have a greater chance of survival were those
studies repeated; this may affect the primary outcome of the meta-analysis.
With data from just two studies (740 women), this review is underpowered to detect a difference in the incidence of death of a
baby or the frequency of a small-for-gestational-age infant as these have a background incidence of approximately 0.75% and 10% of
pregnancies respectively. Similarly, this review is underpowered to detect differences between serious and/or rare adverse events such as
severe neonatal morbidity. Two of the three included studies were quasi-randomised, with significant risk of bias from group allocation.
Additionally, there may be performance bias as in one of the two studies contributing data, participants receiving standard care did not
have venepuncture, so clinicians treating participants could identify which arm of the study they were in. Future studies should consider
more robust randomisation methods and concealment of group allocation and should be adequately powered to detect differences in
rare adverse events.
The studies identified in this review examined two different analytes: oestrogens and hPL. There are many other placental products
that could be employed as surrogates of placental function, including: placental growth factor (PlGF), human chorionic gonadotrophin
(hCG), plasma protein A (PAPP-A), placental protein 13 (PP-13), pregnancy-specific glycoproteins and progesterone metabolites and
further studies should be encouraged to investigate these other placental products. Future randomised controlled trials should test
analytes identified as having the best predictive reliability for placental dysfunction leading to small-for-gestational-age infants and
perinatal mortality.
P L A I N L A N G U A G E S U M M A R Y
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Using biochemical tests to measure placental function and improve pregnancy outcomes
What is the issue and why is it important?
The placenta (afterbirth) develops in the uterus during pregnancy to provide oxygen and nutrients to the growing baby and to remove
waste products from the baby’s blood. The placenta attaches to the wall of the uterus and is linked to the baby via the umbilical cord.
The placenta plays a critical role in determining the health of the baby and mother. The health of the placenta can be assessed by
performing tests on mothers’ blood or urine to measure chemicals made by the placenta. Having this information could improve the
outcome of pregnancy as professionals could intervene to prevent outcomes such as stillbirth or babies being born too small.
What evidence did we find?
We included three randomised controlled studies. Two trials were at a high risk of bias and one was at a low risk of bias. One study
did not contribute any data towards this review. Therefore, this review is based on data from two studies involving 740 mothers. The
evidence from these studies was graded as either low or very low quality evidence.
We found insufficient evidence to draw any conclusions about the effectiveness of tests that measure placental health in reducing the
number of babies that die before birth (very low quality evidence) or shortly after birth (very low quality evidence), or in reducing the
number of babies that are born small for their gestational age (low quality evidence).There was no evidence to suggest that measurement
of placental health could cause harm by increasing intervention (planned delivery or caesarean section (low quality evidence) or increasing
mothers’ anxiety levels. There was no change in the number of babies admitted to the neonatal intensive care unit or the proportion
of babies born before 37 weeks gestation (low quality evidence). There were no reports of serious disease for babies (as reported in one
study only) or maternal deaths in any of the studies. A number of this review’s other outcomes of interest were not reported in the
included studies.
More research is needed to determine the most useful test for placental health as a way of predicting poor pregnancy outcome, and
then to investigate whether performing this test on mothers improves pregnancy outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Test of placental function compared with standard care for improving pregnancy outcome
Patient or population: women in the third trimester of pregnancy
Settings: antenatal clinic or antenatal assessment unit
Intervention: test of placental function
Comparison: standard care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard care Test of placental func-
tion
Death of a baby (still-
birth or neonatal death)
report of perinatal death
Study population RR 0.88
(0.36 to 2.13)
740
(2 studies)
⊕©©©
very low1
27 per 1000 24 per 1000
(10 to 58)
Low
15 per 1000 13 per 1000
(5 to 32)
High
29 per 1000 26 per 1000
(10 to 62)
Stillbirth
report of stillbirth
Study population2 RR 0.56
(0.16 to 1.88)
740
(2 studies)
⊕©©©
very low1,3,4
19 per 1000 11 per 1000
(3 to 36)
Low2
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15 per 1000 8 per 1000
(2 to 28)
High2
29 per 1000 16 per 1000
(5 to 55)
Neonatal death
report of neonatal death
Study population RR 1.62
(0.39 to 6.74)
740
(2 studies)
⊕©©©
very low1,4,5
8 per 1000 13 per 1000
(3 to 55)
Low
0 per 1000 0 per 1000
(0 to 0)
High
29 per 1000 47 per 1000
(11 to 195)
Small-for-gestational
age (below 10th cen-
tile on customised birth-
weight chart or as de-
fined by trialists)
birthweight centile chart
Study population RR 0.44
(0.16 to 1.19)
118
(1 study)
⊕⊕©©
low4,6
190 per 1000 83 per 1000
(30 to 226)
Moderate
190 per 1000 84 per 1000
(30 to 226)
Preterm birth (before 37
weeks’ gestation)
reported gestation at birth
Study population7 RR 2.90
(0.12 to 69.81)
118
(1 study)
⊕⊕©©
low4,8
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0 per 1000 0 per 1000
(0 to 0)
Low7
60 per 1000 174 per 1000
(7 to 1000)
High7
80 per 1000 232 per 1000
(10 to 1000)
Elective delivery (induc-
tion of labour or non-
labour caesarean sec-
tion)
report of mode of delivery
Study population RR 0.98
(0.84 to 1.14)
740
(2 studies)
⊕⊕©©
low1,4
485 per 1000 475 per 1000
(407 to 553)
Moderate
533 per 1000 522 per 1000
(448 to 608)
Caesarean section
report of mode of delivery
Study population RR 0.48
(0.15 to 1.52)
118
(1 study)
⊕⊕©©
low4,9
138 per 1000 66 per 1000
(21 to 210)
Moderate
138 per 1000 66 per 1000
(21 to 210)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Duenhoelter 1976 had a high risk of bias in the following domains: random sequence generation and allocation concealment, and
unclear for blinding of participants. Heazell 2013 had a high risk of bias in the blinding of participants domain.
2 Risk of stillbirth in women presenting with reduced fetal movements reported to be three-fold greater than infants with normal
movements (~1.5%). Population in Duenhoelter 1976 very heterogenous population, but the overall perinatal mortality rate at the unit
was 2.9%.
3 Few stillbirths in included studies.11 stillbirths in Duenhoelter 1976 and none in Heazell 2013. Total sample size for comparison = 740.
4 At least one study known to have commenced but discontinued (Grudzinskas 1990).
5 Few neonatal deaths in included studies; 8 neonatal deaths in Duenhoelter 1976 and none in Heazell 2013. Total sample size for
comparison = 740.
6 Few small-for-gestational-age births in included studies. Heazell 2013 included 16 small-for-gestational-age births in total sample size
for comparison = 120.
7 O’Sullivan 2009 report a preterm delivery rate of 6% in women attending with reduced fetal movements. ~8% of births occur before 37
weeks’ gestation.
8 One preterm birth reported in included study (Heazell 2013) from total sample size for comparison = 120.
9 Few caesarean deliveries (n = 12) reported in one study (Heazell 2013) with a total of 120 participants.
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B A C K G R O U N D
In a healthy pregnancy, the placenta is a metabolically active en-
docrine organ secreting many different hormones and metabo-
lites into maternal blood; this profile may alter with pregnancy
complications (Conde-Agudelo 2013). The outcome of pregnancy
is closely linked to placental function; placental dysfunction has
been documented in complications of pregnancy including: fetal
growth restriction, small-for-gestational-age infants, pre-eclamp-
sia, preterm birth, reduced fetal movements and stillbirth (Brosens
2011; Ness 2006; Pinar 2014; Warrander 2012).
Biochemical tests of placental function measure released placental
factors in maternal biofluid(s), including urine and blood. A pre-
vious Cochrane systematic review found no evidence that measur-
ing oestriol improved pregnancy outcome (Neilson 2012). Since
Neilson 2012 was published, there has been increased interest in
the measurement of biomarkers of placental function. Our review
updates the Neilson 2012 review on this topic, and includes more
recently developed biomarkers.
Description of the intervention
Prior to the widespread use of ultrasound to assess fetal biome-
try or biophysical profile from the mid-1970s onwards, biochem-
ical tests of placental function including: oestriol, human placen-
tal lactogen (hPL) and human chorionic gonadotrophin (hCG)
were used in antepartum assessment of the fetus in late pregnancy
(Greene 1965). These biochemical factors were measured in ma-
ternal plasma, serum or urine. Levels of these factors may change
through pregnancy; factors which are synthesised by the placenta
tend to increase in proportion to placental mass throughout preg-
nancy. Important exceptions to this are hCG which peaks in the
first trimester and free placental growth factor (PlGF), which de-
clines after 36 weeks (Saffer 2013). Therefore, performance of spe-
cific biochemical tests may depend on the gestation at sampling.
Recently, biochemical markers related to placental function have
been used as part of maternal serum screening for trisomy 21 in
the first and second trimester including alpha fetoprotein (AFP),
hCG, unconjugated oestriol, pregnancy-associated plasma pro-
tein A (PAPP-A), and inhibin. Observational studies have demon-
strated that in the absence of chromosomal or structural anoma-
lies, dysregulation of these placental biomarkers is associated with
altered risks of fetal death, fetal growth restriction, small-for-ges-
tational-age infants or pre-eclampsia (Dugoff 2004; Smith 2007a;
Smith 2007b). These were either case-control or cohort studies
which focused on samples obtained in first trimester screening.
SerumPAPP-A below 5th centile (0.42MoM) was associated with
an increased risk of spontaneous loss before 24 weeks’ gestation
(odds ratio (OR) 2.50, 95%confidence interval (CI) 1.76 to 3.56),
stillbirth (OR 2.15, 95% CI 1.11 to 4.15), small-for-gestational
age below 10th centile (OR 2.47, 95% CI 2.16 to 2.81) and pre-
eclampsia (OR 1.54, 95% CI 1.16 to 2.03); hCG below 5th cen-
tile was related to small-for-gestational-age infant below 10th cen-
tile (OR 1.55, 95% CI 1.33 to 1.80) (Dugoff 2004). Measure-
ments obtained in the second trimester (15 to 21 weeks) found
that women with increased AFP greater than 95th centile had an
elevated risk of stillbirth (OR 2.79, 95% CI 2.09 to 3.73); this
was also true for hCG greater than 95th centile (OR 1.93, 95%
CI 1.39 to 2.66) (Smith 2007a).
Recently, placentally-derived factors in maternal blood includ-
ing hPL (Dutton 2012), placental protein 13 (PP-13) (Schneuer
2012), soluble FMS-like tyrosine kinase (sFLt-1) (Smith 2007b),
PlGF (Benton 2012), and various metabolites (Horgan 2011),
have been measured by a variety of different experimental ap-
proaches including: enzyme-linked immunosorbent assay, mass
spectrometry or developed point of care tests. Elevated sFlt-1 in
the first trimester is associated with a reduced risk of a small-for-
gestational-age infant (OR 0.92, 95% CI 0.88 to 0.96), and still-
birth associated with a placental cause (OR 0.77, 95% CI 0.61 to
0.95). Likewise, high PlGF in the first trimester is associated with
a reduction in small-for-gestational-age infant (OR 0.95, 95% CI
0.90 to 0.99) (Smith 2007b). Measurement of PlGF in the third
trimester differentiated placental intrauterine growth restriction
(IUGR) (n = 9) from constitutionally small fetuses (n = 7) with
100% sensitivity and 86% specificity (Benton 2012).
Currently, ultrasound assessment of fetal well-being provides only
modest benefits in selected populations (Alfirevic 2013; Alfirevic
2015). This has increased interest in othermethods of predicting or
identifying fetal compromise. It is hypothesised that measurement
of biochemical factors in maternal blood or urine reflects placental
function, which is closely linked to fetal outcome compromise.
How the intervention might work
Many pregnancy complications are related to abnormal placental
function; methods which assess placental function may identify
pregnancies where placental dysfunction is sufficiently severe that
it leads to fetal demise. It is hypothesised that revealing the results
of these biochemical measurements to clinicians may improve de-
tection of complications, which could improve pregnancy out-
come by targeting intervention (e.g. delivery). However, it is also
possible that the intervention could have negative effects includ-
ing: increased maternal anxiety due to increased testing or abnor-
mal results, or increased intervention such as induction of labour
or caesarean section.
Why it is important to do this review
Observational studies relating abnormal levels of placentally-de-
rived factors to increased risk of stillbirth, fetal growth restriction
and pre-eclampsia have re-ignited interest in biochemical markers
of placental dysfunction. Therefore, it is important to determine
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the value of biochemical tests of placental function in improving
fetal and maternal outcome of pregnancy.
O B J E C T I V E S
To assess whether clinicians’ knowledge of the results of biochem-
ical tests of placental function is associated with an improvement
in fetal or maternal outcome of pregnancy in high-risk, low-risk
or unselected pregnancies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised and quasi-randomised trials that assessed
the effects of biochemical testing of placental or feto-placental
function in pregnancy. Cluster-randomised trials were eligible for
inclusion. Cross-over randomised trials were not eligible for inclu-
sion as this is not an appropriate study design for this question. We
included studies reported only as abstracts, provided there were
sufficient data to evaluate study quality.
Types of participants
All pregnant women, regardless of whether deemed to be high
risk or low risk for pregnancy complications (e.g. fetal growth re-
striction, perinatal mortality or pre-eclampsia), or unselected par-
ticipants by the study investigators. Women who had pregnan-
cies complicated by chromosomal or structural anomaly were ex-
cluded.
Types of interventions
Studies were eligible if they compared women who had placental
function tests and the results were available to their clinicians with
women who either did not have the tests, or the tests were done
but the results were not available to the clinicians. The placental
function tests were any biochemical test of placental function car-
ried out using the woman’s maternal biofluid, either alone or in
combination with other placental function test/s.
Types of outcome measures
Primary outcomes
1. Death of a baby (stillbirth or neonatal death)
2. Small-for-gestational age (below 10th centile on customised
birthweight chart, or as defined by trialists)
Secondary outcomes
For the baby
1. Stillbirth
2. Neonatal death
3. Umbilical artery pH < 7.0
4. Neonatal intensive care unit admission
5. Neonatal intensive care for more than seven days
6. Preterm birth (before 37 weeks’ gestation)
7. Very preterm birth (before 32 weeks’ gestation)
8. Need for ventilation
9. Organ failure
10. Serious neonatal morbidity (e.g. necrotising enterocolitis,
chronic lung disease, intraventricular haemorrhage, sepsis,
seizures)
11. Fetal abnormality
12. Neurodevelopment in childhood (cerebral palsy,
neurodevelopmental delay)
For the women
1. Elective delivery (induction of labour or non-labour
caesarean section)
2. Caesarean section
3. Intensive care admission
4. High-dependency unit admission
5. Hospital admission for ≥ seven days
6. Pre-eclampsia
7. Eclampsia
8. Maternal death
9. Women’s perception of care
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (31 July
2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
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3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
Selection of studies
Two review authors (Alexander Heazell (AEPH) and Melissa
Whitworth (MKW)) independently assessed studies identified by
the search strategy for inclusion. Disagreement was resolved by
discussion or, if required, consultation with a third review author
(Lelia Duley (LD) or Jim Thornton (JT)). Where there were con-
flicts of interest due to authorship of an included trial, studies were
selected for inclusion by a review author who was not an author
of the relevant trial report.
Data extraction and management
A form was designed to extract data. For eligible studies, AEPH
andMKWextracted the data using the agreed form.Discrepancies
were resolved through discussion or, if required, consultation with
LD or JT.Where there were conflicts of interest due to authorship,
data were extracted by a review author who was not an author of
the relevant trial report. Data were entered into Review Manager
software (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
AEPH and MKW independently assessed each study for risk of
bias using the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Disagreement was
resolved by discussion. Where there were conflicts of interest due
to authorship, the risk of bias was assessed by a review author who
was not an author of the relevant trial report.
(1) Random sequence generation (checking for possible
selection bias)
For each included study, we described themethod used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study, we described the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received.We considered that studies are
at low risk of bias if they were blinded, or if we judged that the
lack of blinding was unlikely to affect results.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we described the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. Where relevant, we assessed blinding sepa-
rately for different outcomes or classes of outcomes.
Methods used to blind outcome were assessed as:
• low, high or unclear risk of bias.
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(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described the completeness of data including attrition and
exclusions from the analysis for each included study. We stated
whether attrition and exclusions were reported and the numbers
included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion where
reported, and whether missing data were balanced across groups
or were related to outcomes. Where sufficient information was
reported, or could be supplied by the trial authors, we re-included
missing data in the analyses which we undertook.
Methods were assessed as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We investigated the possibility of selective outcome reporting bias.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study we described any important concerns
about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made judgements about whether studies were at high risk of
bias, according to the criteria given in the Handbook (Higgins
2011). With reference to (1) to (6) above, we assessed the likely
magnitude and direction of the bias and whether we considered
it is likely to impact on the findings. We explored the impact of
the level of bias by undertaking sensitivity analyses - see Sensitivity
analysis.
Using the GRADE approach to assess the quality of
the body of evidence
For this review, we assessed the quality of the evidence using the
GRADE approach as outlined in the GRADE handbook in order
to assess the quality of the body of evidence relating to the follow-
ing outcomes for the main comparison (tests of placental function
versus standard care).
1. Death of a baby (stillbirth or neonatal death)
2. Small-for-gestational age (below 10th centile on customised
birthweight chart or as defined by trialists)
3. Stillbirth
4. Neonatal death
5. Preterm birth (before 37 weeks’ gestation)
6. Elective delivery (induction of labour or non-labour
caesarean section)
7. Caesarean section
GRADEpro Guideline Development Tool was used to import
data from Review Manager (RevMan 2014) in order to create
a ’Summary of findings’ table. A summary of the intervention
effect and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, results are presented as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the mean difference if
outcomes were measured in the same way between trials and the
standardised mean difference to combine trials that measured the
same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
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We did not identify any cluster-randomised for inclusion in the
analysis. In future updates, if trials are identified and found to
be eligible, we will include cluster-randomised trials in the analy-
ses along with individually-randomised controlled trials. We will
adjust their standard errors using the methods described in the
Handbook [Section 16.3.6] using an estimate of the intracluster
correlation co-efficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we
use ICCs from other sources, we will report this and conduct sen-
sitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Studies with a cross-over design were not eligible for inclusion, as
this design is not appropriate for this question.
Studies with multiple treatment groups
We did not identify any studies with multiple treatment groups.
In future updates, if such trials are identified and found to be el-
igible, we will include them if any pair-wise comparisons of the
intervention groups are relevant to the review and meet the inclu-
sion criteria. We will report all the intervention groups involved
in the index study in the Characteristics of included studies table,
but will include only those intervention groups relevant to the
analysis. We will address pair-wise comparisons from multi-arm
trials in meta-analyses, if they are eligible. We will ensure that data
from individual participants are only included once when pooling
data. If there are multiple intervention groups in a particular meta-
analysis, we will combine all relevant experimental intervention
groups of the study into a single intervention group and combine
all relevant control intervention groups into a single control group
(Higgins 2011).
Dealing with missing data
For included studies, we noted levels of attrition. We had planned
to explore the impact of including studies with high levels of miss-
ing data in the overall assessment of treatment effect by using sen-
sitivity analysis if a sufficient number of studies were identified.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either a T² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
Had there been10ormore studies in themeta-analysis, we planned
to investigate reporting biases (such as publication bias) using fun-
nel plots. No meta-analysis had more than 10 studies. In future
updates, if there are 10 or more trials we will assess funnel plot
asymmetry visually. If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. In future updates, if
there is clinical heterogeneity sufficient to expect that the under-
lying treatment effects differed between trials, or if substantial sta-
tistical heterogeneity is detected, we will use random-effects meta-
analysis to produce an overall summary, if an average treatment ef-
fect across trials is considered clinically meaningful. The random-
effects summary will be treated as the average range of possible
treatment effects and we will discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect is not clinically meaningful, we will not combine trials.
In future updates, if we use random-effects analyses, the results
will be presented as the average treatment effect with its 95%
confidence interval, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We did not identify substantial heterogeneity in our analyses.
However, in future updates, if we identify substantial heterogene-
ity, we will investigate it using subgroup and sensitivity analyses.
We will consider whether an overall summary is meaningful, and
if so, will use random-effects analysis to produce it.
We will carry out the following planned subgroup analyses based
on:
1. risk at trial entry: women at high risk, women at low risk;
women with mixed low and high risk or unselected risk; women
with risk status unknown;
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2. risk of bias: low risk of bias; high risk of bias; risk of bias
unclear;
3. type of placental function tests;
4. timing of placental function tests divided by trimester.
Subgroup analysis will be restricted to the review’s primary out-
comes.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2014) and will report the results of
subgroup analyses quoting the χ2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
Wedid not perform sensitivity analysis due to the small number of
trials included. In future updates, if more studies are included, we
will conduct sensitivity analyses to explore the effect of particular
aspects of study quality (e.g. randomised controlled trials versus
quasi-randomised controlled trials) or statistical treatment of data
looking at primary outcomes only.
R E S U L T S
Description of studies
Results of the search
The search of theCochrane Pregnancy andChildbirthGroup’sTri-
als Register in September 2014 retrieved six reports relating to five
studies (see:Figure 1). Three studies were included (Duenhoelter
1976; Heazell 2013; Spellacy 1975), and two were excluded
(Grudzinskas 1990; Sharf 1984).
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Figure 1. Study flow diagram.
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Included studies
We included three studies (Duenhoelter 1976; Heazell 2013;
Spellacy 1975). Bernatavicius 2013 was a preliminary report of an
included study (Heazell 2013). The characteristics of these studies
are shown in Characteristics of included studies.
Design
We included one randomised controlled trial (Heazell 2013)
and two quasi-randomised controlled trials (Duenhoelter 1976;
Spellacy 1975). All of the trials tested a form of biochemical test
in addition to standard antenatal practice compared with standard
antenatal practice alone.
Sample sizes
The studies were of varying size, the smallest had 120 participants
(Heazell 2013), the next had622participants (Duenhoelter 1976),
and the largest study had 2733 participants (Spellacy 1975).
Setting
Two of the three included studies were conducted in the United
States of America (Duenhoelter 1976; Spellacy 1975), and the
third one in the UK (Heazell 2013). All of the studies were con-
ducted in a single centre.
Participants
Two studies included women attending “high-risk” antenatal
clinics or inpatient antenatal service with a variety of different
complications, including: hypertension, diabetes, fetal growth re-
striction, postmaturity, Rhesus disease and a history of stillbirth
(Duenhoelter 1976; Spellacy 1975). The remaining study focused
on women attending the antenatal service of a tertiary maternity
service with maternal perception of reduced fetal movements after
36 weeks of pregnancy (Heazell 2013).
Intervention
One study measured oestrogens (Duenhoelter 1976), and two
measured human placental lactogen (hPL) (Heazell 2013; Spellacy
1975). All studies performed biochemical tests in addition to rou-
tine antenatal care in that clinical setting at the time of that study.
Outcomes
One study did not report on any of the primary or secondary
outcomes of interest for all participants undergoing biochemical
testing (Spellacy 1975). The other two trials reported on the death
of a baby (either stillbirth or neonatal death), and the rate of elec-
tive delivery (Duenhoelter 1976; Heazell 2013). Only one trial re-
ported information on the frequency of caesarean section, preterm
birth before 37 weeks’ gestation, admission to the neonatal inten-
sive care unit and levels of maternal anxiety (Heazell 2013). There
were no cases of serious neonatal morbidity reported in any study.
Maternal death was not reported in any study.
Excluded studies
Two studies were excluded (Grudzinskas 1990; Sharf 1984). Sharf
1984 was excluded as it did not meet the inclusion criteria as it was
not a randomised or quasi-randomised trial. The other study was
excluded because the trial was abandoned before completion with
no results available for the 160 participants (Grudzinskas 1990).
Risk of bias in included studies
The ’Risk of bias’ assessment for included studies is shown in
Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All included studies were randomised. Two studies were quasi-ran-
domised as participants were assigned to different treatment based
upon casenote number given by administrative staff and allocation
was not concealed at the point of randomisation (Duenhoelter
1976; Spellacy 1975). The other study used computer-generated
individual randomisation in a 1:1 ratiowith random variable block
size and it was stated that allocations were concealed from those
enrolling participants to the trial (Heazell 2013).
Blinding
There was an attempt to blindwomen and staff to group allocation
in two studies, in which venepuncture was performed in all cases,
with the result concealed from the clinicians for participants in the
control group, although it was not clear if blinding was successful,
and staff would be aware which women were in the intervention
group once test results were revealed (Duenhoelter 1976; Spellacy
1975). The group allocation was not directly revealed in the other
study, but only participants in the intervention (testing) arm of
the trial had venepuncture performed (Heazell 2013). Therefore,
clinicians providing care for these participants would be aware of
participants’ group allocation.
Incomplete outcome data
Two out of three trials reported complete outcome data for all
participants (Duenhoelter 1976; Heazell 2013). The other trial
only reported outcome from women who had reduced levels of
hPL, interpreted as being in the “danger zone” (Spellacy 1975).
Due to the incomplete outcome reporting in this study, the rates of
outcomes could not be calculated, so no results could be extracted.
Selective reporting
Two studies were conducted in the 1970s and we were unable to
access the protocols (Duenhoelter 1976; Spellacy 1975). However,
Spellacy 1975 did not report all of the data specified in the meth-
ods section of the paper, so this was judged to be at high risk of
bias. Heazell 2013 reported on primary and secondary outcomes
specified in the ISRCTN Registry entry.
Other potential sources of bias
In general, the included studies had an unclear risk of other po-
tential sources of bias. None of the studies included information
about how many participants were screened to be in the study
or who were excluded and for what reason. One study (Heazell
2013) described the number of women and their reasons for non-
participation in the trial.
Effects of interventions
See: Summary of findings for the main comparison Test of
placental function compared with standard care for improving
pregnancy outcome
We included three studies but one study (Spellacy 1975) did not
report on the outcomes of interest in this review. Consequently,
only two studies (740 participants) contributed data towards our
analyses.Due to the small number of trials and outcomes of interest
reported, differences between studies depending on risk of bias or
biochemical analyte could not be assessed.
Test of placental function versus standard care (comparison
1)
Primary outcomes
The included studies of a biochemical test of placental function
do not show evidence of a clear difference in the incidence of the
death of a baby (risk ratio (RR) 0.88, 95% confidence interval
(CI) 0.36 to 2.13, two trials, 740 participants (Analysis 1.1)) or the
frequency of a small-for-gestational-age infant (RR 0.44, 95%
CI 0.16 to 1.19, one trial, 118 participants (Analysis 1.2)).
Secondary outcomes
There was no evidence of a clear difference between the incidence
of stillbirth (RR 0.56, 95% CI 0.16 to 1.88, two trials, 740 par-
ticipants (Analysis 1.3)), or neonatal death (RR 1.62, 95% CI
0.39 to 6.74, two trials, 740 participants (Analysis 1.4)) when
women had biochemical tests of placental function compared with
standard care, although the directions of any potential effect were
in opposing directions. There was no evidence of a difference in
any of the secondary outcome measures between women who had
biochemical tests of placental function or standard care, includ-
ing: neonatal intensive care admission (RR 0.32, 95% CI 0.03
to 3.01, one trial, 118 participants (Analysis 1.5)), preterm birth
(before 37 weeks’ gestation) (one trial, RR 2.90, 95% CI 0.12 to
69.81, one trial, 118 participants (Analysis 1.6)), serious neonatal
morbidity (one trial, but RR not estimable as no events (Analysis
1.7)), elective delivery (induction of labour or non-labour cae-
sarean section) (RR 0.98, 95% CI 0.84 to 1.14, two trials, 740
participants (Analysis 1.8)), or caesarean section (RR 0.48, 95%
CI 0.15 to 1.52, one trial, 118 participants (Analysis 1.9)). Ma-
ternal death was not reported in any study.
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Outcomes not reported in the included studies
A number of this review’s secondary outcomes relating to the baby
were not reported in the included studies: umbilical artery pH <
7.0, neonatal intensive care for more than seven days, very preterm
birth (< 32 weeks’ gestation), need for ventilation, organ failure,
fetal abnormality, neurodevelopment in childhood (cerebral palsy,
neurodevelopmental delay). Similarly, a number of this review’s
maternal secondary outcomes were not reported in the included
studies, these are: admission to intensive care, high dependency
unit admission, hospital admission for > seven days, pre-eclampsia,
eclampsia, and women’s perception of care.
Non-prespecified secondary outcome
There was evidence of a reduction in the mean anxiety score of
women who had biochemical tests of placental function compared
with standard antenatal care (one trial,meandifference -2.48, 95%
CI -4.78 to -0.02; Analysis 1.10).
D I S C U S S I O N
Summary of main results
The utility of a biochemical test of placental function has two
components, i) the predictive reliability of the test and ii) the po-
tentially beneficial or harmful consequences of intervention (de-
livery). There are an insufficient number of randomised controlled
trials describing both the primary and secondary outcomes to eval-
uate the utility of biochemical tests of placental function. There
was no clear evidence of any difference between groups for death
of a baby, or in the components of this outcome, stillbirth and
neonatal death where the directions of any potential effect were in
opposing directions. Critically, this meta-analysis is underpowered
to identify a significant difference in all three of these outcomes.
There was insufficient evidence to evaluate whether biochemical
tests of placental function altered the frequency of a small-for-
gestational-age infant. The use of biochemical tests of placental
function did not appear to be associated with potential harms
such as an increase in obstetric intervention (elective delivery or
caesarean section), preterm birth (< 37 weeks) or admission to the
neonatal intensive care unit.
Data from one trial that assessed maternal anxiety (a non-prespec-
ified outcome) suggest that this was lower in women who had
tests of placental function. However, a reduction in the state trait
anxiety score of 2.4 is unlikely to be clinically significant as the
scale ranges from 20 to 80, and no threshold has yet been set for
a significant reduction in state anxiety.
Overall completeness and applicability of
evidence
Two of the trials were performed in the 1970s on women with a
variety of antenatal complications, some of which are unrelated to
placental dysfunction (e.g. rhesus isoimmunisation). The evidence
from these studies cannot be generalised to women at low-risk of
complications or groups of women with specific pregnancy com-
plications (e.g. fetal growth restriction). Furthermore, outcomes
described in the 1970s may not reflect what would be expected
at present. For example, neonatal mortality rates have fallen sub-
stantially, such that an infant delivered at 28 weeks would have
a greater chance of survival were those studies repeated; this may
affect the primary outcome of the meta-analysis.
As this review included data from only two studies with 740 par-
ticipants overall, it is underpowered to detect a difference in the
incidence of death of a baby or the frequency of a small-for-gesta-
tional-age infant as these have a background incidence of approxi-
mately 0.75% and 10% of pregnancies, respectively. Similarly, this
review is underpowered to detect differences between serious and/
or rare adverse events such as severe neonatal morbidity such as
hypoxic-ischaemic encephalopathy. This limitation must be con-
sidered when developing adequately powered future clinical trials
to evaluate biochemical tests of placental function and performing
subsequent meta-analyses.
Quality of the evidence
Twoout of the three studies included in this reviewwere quasi-ran-
domised sohad significant risk of bias fromgroup allocation. In ad-
dition, there may be performance bias as in one study participants
receiving standard care did not have venepuncture, so clinicians
treating participants could identify which arm of the study they
were in. Future studies should consider more robust randomisa-
tion methods and concealment of group allocation e.g. venepunc-
ture could be performed on all participants with restricted mea-
surement of the analyte or disclosure of results in the treatment
group.
Potential biases in the review process
There were no biases identified in the review process.
Agreements and disagreements with other
studies or reviews
Although this analysis identified and included one more trial, the
review’s findings are in agreement with the previous systematic
review and meta-analysis conducted by Neilson (Neilson 2012).
We are not aware of other studies that have systematically reviewed
this topic.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the available data, there are insufficient data to evaluate
whether biochemical tests of placental function can reduce peri-
natal mortality or increase identification of small-for-gestational-
age infants. We were only able to identify data from two studies
(involving a total of 740 participants) that measured oestrogens
and human placental lactogen (hPL). These studies were under-
powered to detect differences in pregnancy outcome.
Implications for research
Biochemical tests of placental function offer an opportunity to
evaluate placental health in utero which is inextricably linked with
fetal well-being (Heazell 2015).The studies identified in this re-
view described prospective studies of two different analytes: oe-
strogens and hPL. There are many other placental products that
could be employed as surrogates of placental function, including:
placental growth factor (PlGF), human chorionic gonadotrophin
(hCG), pregnancy-associated plasma protein A (PAPP-A), placen-
tal protein 13 (PP-13), pregnancy-specific glycoproteins and pro-
gesterone metabolites. None of these have been tested in prospec-
tive randomised studies. Such randomised controlled trials should
test analytes identified as having the best predictive reliability for
placental dysfunction leading to small-for-gestational-age infants
and perinatal mortality. If further studies are conducted thenmeta-
analyses could address whether there are differences in perinatal
outcome alter depending on the analyte or type of biochemical
test.
It is important to appreciate that any test of fetal or placental com-
promise alone is insufficient to alter pregnancy outcome; a pos-
itive test must be combined with an intervention to prevent an
adverse outcome. This may take the form of increased antenatal
surveillance, e.g. umbilical artery Doppler or delivery. Therefore,
further diagnostic test-accuracy studies should be encouraged to
determine the optimal measurements or combination of measure-
ments to identify placental dysfunction in utero and then inter-
vention studies conducted to determine whether these measure-
ments combined with appropriate intervention (increased screen-
ing or delivery) lead to improved pregnancy outcome for mother
and baby.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Duenhoelter 1976
Methods Parallel group quasi-randomised trial.
Participants 622 women attending obstetric complications outpatient clinic or inpatients on high-
risk obstetric unit. The results of oestrogen levels were reported in 315 women and not
reported in 307 women
Interventions Plasma oestrogen measured and results reported to individual physicians. Delivery ad-
vised if concentration of oestrogen was consistently low, < 20 ng/mL after 34 weeks or
levels suddenly decreased. Comparison group had oestrogen measured but not reported
Outcomes Stillbirths, neonatal deaths, spontaneous labour, primary induction of labour, primary
caesarean section
Notes Unable to assess overall caesarean section rate asmode of delivery not reported for women
who went into spontaneous labour
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Numbers assigned by administrative staff based
on casenote number
Allocation concealment (selection bias) High risk Randomised based on casenote number, so al-
location not concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Women in both arms had oestrogen measured
but results were not reported in the control
group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors were
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data reported for all participants.
Selective reporting (reporting bias) Unclear risk Cannot assess as authors did not state what out-
comes they would analyse
Other bias Unclear risk No evidence of how many potential partici-
pants were screened. No evidence of differences
in baseline characteristics between intervention
and control groups. No evidence of different
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Duenhoelter 1976 (Continued)
diagnostic activity between the 2 groups
Heazell 2013
Methods Parallel-group randomised trial.
Participants 120 women attending a tertiary centre with maternal perception of reduced fetal move-
ments after 36 weeks’ gestation; 60 women were randomised to each arm of the study.
Women were excluded if there was a known congenital anomaly, multiple pregnancy,
fetus required immediate delivery, maternal age < 17 or unable to give informed consent
Interventions Measurement of serum human placental lactogen and ultrasound assessment of fetal
biometry, umbilical arteryDoppler and liquor volume compared to ultrasound biometry,
umbilical artery Doppler and liquor volume alone if met unit protocol
Outcomes Stillbirth, neonatal death, small-for-gestational age (< 10th centile on customised birth-
weight chart), umbilical artery pH ≤ 7,1, unexpected admission to the neonatal inten-
sive care unit, maternal anxiety (STAI score)
Notes Preliminary data from this study was also reported in Bernatavicius 2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generation by computer algorithm,using
varying block size
Allocation concealment (selection bias) Low risk Clinicians enrolling to the trial were unable to pre-
dict participant allocation, which was achieved using
a secure web-based randomisation system using in-
dividual randomisation in a 1:1 ratio with random
variable block size. Upcoming allocations were con-
cealed from those enrolling participants to the trial
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel and participants were not blinded to group
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor was blind to group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary and secondary outcomes were reported for
all participants
Selective reporting (reporting bias) Low risk All data specified in the trial registration and protocol
were reported
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Heazell 2013 (Continued)
Other bias Low risk Number of participants approached to participate
and number of participants consented presented.
No report of the number of potential participants
screened for eligibility. No evidence of differences
in baseline characteristics between intervention and
control groups. No evidence of different diagnostic
activity between the 2 groups
Spellacy 1975
Methods Quasi-randomised trial.
Participants 2733 women attending a high-risk pregnancy clinic with conditions including: hyper-
tension, diabetes mellitus, fetal growth restriction, rhesus isoimmunisation, previous
stillbirth, postmaturity and collagen diseases. The result was revealed to clinicians for
the 1362 women in the intervention group and not revealed for the 1371 women in the
control group
Interventions Measurement of human placental lactogen reported in intervention group, results were
concealed in women in control group
Outcomes Stillbirth, neonatal death, Apgar scores at 1 and 5 minutes of age
Notes Although this study met the inclusion criteria, data could not be extracted as they were
only reported for women who had a low (fetal danger zone) hPL result
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised trial with sequence based on casenote
number (odd or even)
Allocation concealment (selection bias) High risk Not concealed as case number known.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Both groups had similar case notes and both had venepunc-
ture performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessor not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcomes were only reported for participants who had low
hPL levels (referred to as fetal danger zone)
Selective reporting (reporting bias) High risk No reporting of Apgar results, specified in themethods section
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Spellacy 1975 (Continued)
Other bias Unclear risk No evidence of how many potential participants were
screened. Unable to assess whether there was evidence of dif-
ferences in baseline characteristics between intervention and
control groups. No evidence of different diagnostic activity
between the 2 groups
hPL: human placental lactogen
STAI: state trait anxiety index
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Grudzinskas 1990 Trial protocol only. Letter indicating that trial commenced but that it ceased to recruit after 160 women were
recruited; the trial was abandoned prior to completion
Sharf 1984 Although stated to be a randomised study in the abstract, the methods section describes a non-randomised study
with patients assigned to a control group or intervention arm. Therefore, study excluded as not a randomised
or quasi-randomised trial
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D A T A A N D A N A L Y S E S
Comparison 1. Test of placental function versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death of a baby (stillbirth or
neonatal death)
2 740 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.36, 2.13]
2 Small-for-gestational age (below
10th centile on customised
birthweight chart or as defined
by trialists)
1 118 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.16, 1.19]
3 Stillbirth 2 740 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.16, 1.88]
4 Neonatal death 2 740 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.39, 6.74]
5 Neonatal intensive care unit
admission
1 118 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.01]
6 Preterm birth (before 37 weeks’
gestation)
1 118 Risk Ratio (M-H, Fixed, 95% CI) 2.90 [0.12, 69.81]
7 Serious neonatal morbidity
(e.g. necrotising enterocolitis,
chronic lung disease,
intraventricular haemorrhage,
sepsis, seizures)
1 118 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Elective delivery (induction of
labour or non-labour caesarean
section)
2 740 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.84, 1.14]
9 Caesarean section 1 118 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.52]
10 Change in state anxiety score 1 118 Mean Difference (IV, Fixed, 95% CI) -2.40 [-4.78, -0.02]
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Analysis 1.1. Comparison 1 Test of placental function versus standard care, Outcome 1 Death of a baby
(stillbirth or neonatal death).
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 1 Death of a baby (stillbirth or neonatal death)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duenhoelter 1976 9/315 10/307 100.0 % 0.88 [ 0.36, 2.13 ]
Heazell 2013 0/60 0/58 Not estimable
Total (95% CI) 375 365 100.0 % 0.88 [ 0.36, 2.13 ]
Total events: 9 (Experimental), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
Analysis 1.2. Comparison 1 Test of placental function versus standard care, Outcome 2 Small-for-
gestational age (below 10th centile on customised birthweight chart or as defined by trialists).
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 2 Small-for-gestational age (below 10th centile on customised birthweight chart or as defined by trialists)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2013 5/60 11/58 100.0 % 0.44 [ 0.16, 1.19 ]
Total (95% CI) 60 58 100.0 % 0.44 [ 0.16, 1.19 ]
Total events: 5 (Experimental), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
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Analysis 1.3. Comparison 1 Test of placental function versus standard care, Outcome 3 Stillbirth.
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 3 Stillbirth
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duenhoelter 1976 4/315 7/307 100.0 % 0.56 [ 0.16, 1.88 ]
Heazell 2013 0/60 0/58 Not estimable
Total (95% CI) 375 365 100.0 % 0.56 [ 0.16, 1.88 ]
Total events: 4 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
Analysis 1.4. Comparison 1 Test of placental function versus standard care, Outcome 4 Neonatal death.
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 4 Neonatal death
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duenhoelter 1976 5/315 3/307 100.0 % 1.62 [ 0.39, 6.74 ]
Heazell 2013 0/60 0/58 Not estimable
Total (95% CI) 375 365 100.0 % 1.62 [ 0.39, 6.74 ]
Total events: 5 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
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Analysis 1.5. Comparison 1 Test of placental function versus standard care, Outcome 5 Neonatal intensive
care unit admission.
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 5 Neonatal intensive care unit admission
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2013 1/60 3/58 100.0 % 0.32 [ 0.03, 3.01 ]
Total (95% CI) 60 58 100.0 % 0.32 [ 0.03, 3.01 ]
Total events: 1 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control]
Analysis 1.6. Comparison 1 Test of placental function versus standard care, Outcome 6 Preterm birth
(before 37 weeks’ gestation).
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 6 Preterm birth (before 37 weeks’ gestation)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2013 1/60 0/58 100.0 % 2.90 [ 0.12, 69.81 ]
Total (95% CI) 60 58 100.0 % 2.90 [ 0.12, 69.81 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
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Analysis 1.7. Comparison 1 Test of placental function versus standard care, Outcome 7 Serious neonatal
morbidity (e.g. necrotising enterocolitis, chronic lung disease, intraventricular haemorrhage, sepsis, seizures).
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 7 Serious neonatal morbidity (e.g. necrotising enterocolitis, chronic lung disease, intraventricular haemorrhage, sepsis, seizures)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2013 0/60 0/58 Not estimable
Total (95% CI) 60 58 Not estimable
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
Analysis 1.8. Comparison 1 Test of placental function versus standard care, Outcome 8 Elective delivery
(induction of labour or non-labour caesarean section).
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 8 Elective delivery (induction of labour or non-labour caesarean section)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duenhoelter 1976 141/315 142/307 80.2 % 0.97 [ 0.81, 1.15 ]
Heazell 2013 37/60 35/58 19.8 % 1.02 [ 0.77, 1.36 ]
Total (95% CI) 375 365 100.0 % 0.98 [ 0.84, 1.14 ]
Total events: 178 (Experimental), 177 (Control)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
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Analysis 1.9. Comparison 1 Test of placental function versus standard care, Outcome 9 Caesarean section.
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 9 Caesarean section
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heazell 2013 4/60 8/58 100.0 % 0.48 [ 0.15, 1.52 ]
Total (95% CI) 60 58 100.0 % 0.48 [ 0.15, 1.52 ]
Total events: 4 (Experimental), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Intervention Favours Control
Analysis 1.10. Comparison 1 Test of placental function versus standard care, Outcome 10 Change in state
anxiety score.
Review: Use of biochemical tests of placental function for improving pregnancy outcome
Comparison: 1 Test of placental function versus standard care
Outcome: 10 Change in state anxiety score
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heazell 2013 60 5.2 (6.7) 58 7.6 (6.5) 100.0 % -2.40 [ -4.78, -0.02 ]
Total (95% CI) 60 58 100.0 % -2.40 [ -4.78, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Intervention Favours Control
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